Na Yeon Kim Net Worth

Na Yeon Kim biography

Na Yeon Kim serves as Independent Chairman of the Board of the Company. Prior to that, she had served on the Board of Private NeuroBo (as defined below) since April 2018. Ms. Kim also currently serves as the Chief Executive Officer of E&Investment, Inc., a South Korean venture capital firm specializing in investments in life sciences companies, a position she has held since March 2018. From October 2015 until March 2018, Ms. Kim was a Representative Director for The SEED Investment Co., Ltd. (formerly known as OST Investment Co., Ltd.), a South Korean investment and fund manager specializing in investments in life sciences companies, and from January 2015 until December 2017, Ms. Kim served as member of the board of directors of Macrogen, Inc., a South Korean, publicly-traded biotechnology company specializing in precision medicine and biotechnology. Ms. Kim also served as an officer of AJUIB Investment, Inc., a venture capital firm headquartered in South Korea specializing in investments in life-science companies from August 2014 until September 2015. Ms. Kim focuses on investment opportunities in a number of industries, particularly in the field of BioPharma, and has more than 15 years of accumulated experience of investment in private equity/venture capital markets. As an investor representative, Ms. Kim has successfully managed more than $400 million in private equity and venture capital funds. Ms. Kim holds an M.S. and B.S. in biomolecular engineering, as well as an M.B.A. from Yonsei University in Korea. Our Board believes Ms. Kim should serve as a director based on her specialized knowledge in building values in life sciences companies and her extensive investment management experience.

How old is Na Kim?

Na Kim is 44, she's been the Independent Chairman of the Board of NeuroBo Pharmaceuticals Inc since 2019. There are 10 older and 1 younger executives at NeuroBo Pharmaceuticals Inc. The oldest executive at NeuroBo Pharmaceuticals Inc is Michael Salsbury, 70, who is the Independent Director.

What's Na Kim's mailing address?

Na's mailing address filed with the SEC is C/O NEUROBO PHARMACEUTICALS, INC., 200 BERKELEY STREET, OFFICE 19TH FLOOR, BOSTON, MA, 02116.

Insiders trading at NeuroBo Pharmaceuticals Inc

Over the last 5 years, insiders at NeuroBo Pharmaceuticals Inc have traded over $0 worth of NeuroBo Pharmaceuticals Inc stock and bought 2,544,530 units worth $7,964,379 . The most active insiders traders include St Co., Ltd Dong A, Tae Heum Jeong e Steven R. Ph.D. Gullans. On average, NeuroBo Pharmaceuticals Inc executives and independent directors trade stock every 0 days with the average trade being worth of $9,541,988. The most recent stock trade was executed by St Co., Ltd Dong A on 23 June 2024, trading 2,544,530 units of NRBO stock currently worth $7,964,379.

What does NeuroBo Pharmaceuticals Inc do?

neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.

NeuroBo Pharmaceuticals Inc executives and stock owners

NeuroBo Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Dr. Ben Gil Price M.D.,
  CEO & Pres
• Nicola Shannon,
  Vice President - Clinical Operations
• Akash Bakshi,
  Sr. VP & COO
• Michael Miller,
  Investor Relations
• Douglas Swirsky,
  Independent Director
• Michael Salsbury,
  Independent Director
• Jeong Gyun Oh,
  Independent Director
• Tae Heum Jeong,
  Independent Director
• Jason Groves,
  Independent Director
• Mark Versavel,
  Chief Medical Officer
• jeong Gu Kang,
  President, Chief Executive Officer, Interim Chief Financial Officer, Secretary, Treasurer and Director
• Na Yeon Kim,
  Independent Chairman of the Board
• Frank Kondrad,
  VP of Corp. & Bus. Devel.
• Dr. Matthew Bardin BCPS, Pharm.D.,
  Sr. VP of Operations
• Dr. Nadja Mannowetz Ph.D.,
  Sr. VP
• Dr. Andrew Bartynski Ph.D.,
  Sr. VP
• Dr. Gil Price M.D.,
  CEO, Pres & Chief Medical Officer
• Dr. Jeong Gu Kang Ph.D.,
  Pres, CEO, Sec., Interim CFO, Treasurer & Director
• St Co., Ltd Dong A,
  
• Mark A Glickman,
  Director
• Akash Bakshi,
  SVP and COO
• Steven R. Ph.D. Gullans,
  Director
• James Patrick Tursi,
  Director
• Ben Gil Price,
  CEO and President
• D Gordon Strickland,
  Director
• Richard Kang,
  Director
• Inc.E&Healthcare Investment...,
  
• Hyung Heon Kim,
  CEO & President
• Marshall H Woodworth,
  Chief Financial Officer